Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:COPN -7.69%78 Debt-to-EBITDA is 0.74 as of Jun. 2026, which is 393% above its 10-year median of 0.15. GuruFocus rates XSWX:COPN with a GF Score™ of 78/100 and a GF Value™ of CHF40.71 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 689 Drug Manufacturers companies, Cosmo NV ranks better than 76.05% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cosmo NV's Debt-to-EBITDA or its related term are showing as below:
XSWX:COPN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.48 Med: 0.15 Max: 21.45
Current: 0.46
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cosmo NV was 21.45. The lowest was -23.48. And the median was 0.15.
XSWX:COPN's Debt-to-EBITDA is ranked better than 76.05% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs XSWX:COPN: 0.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cosmo NV Debt-to-EBITDA Related Terms
Cosmo NV Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:COPN vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Cosmo NV (XSWX:COPN) has a Debt-to-EBITDA of 0.74 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cosmo NV. This is 393% above median its historical median of 0.15. According to the industry distribution chart, Cosmo NV ranks #165 out of 689 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Cosmo NV's Debt-to-EBITDA too high?
Cosmo NV's current Debt-to-EBITDA of 0.74 is 393% above median its 10-year median of 0.15. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Cosmo NV's value of 0.74 is 56% below this industry median. Based on the distribution chart, Cosmo NV ranks #165 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #165 out of 689 companies for Debt-to-EBITDA. This places Cosmo NV in the top 24% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. Cosmo NV's value of 0.74 is 56% below this benchmark. While the company's 10-year median is 0.15 vs. the industry median of 1.68, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Debt-to-EBITDA of 0.74 is 56% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cosmo NV. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Debt-to-EBITDA is 0.74, which is 393% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:COPN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.71, compared to a current price of CHF63.60 — trading 56.2% above its estimated fair value. The current Debt-to-EBITDA is 0.74, which is 393% above median its 10-year median of 0.15 and 56% below the Drug Manufacturers industry median of 1.68. Cosmo NV's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cosmo NV (XSWX:COPN), the current Debt-to-EBITDA is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:COPN) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF63.60 is trading 56.2% above its estimated GF Value™ of CHF40.71.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:COPN:
Debt-to-EBITDA: 0.74 (393% above median its 10-year median of 0.15)
GF Value™: CHF40.71 vs. price of CHF63.60 (56.2% above fair value)
Industry Position: 56% below the Drug Manufacturers median (#165 of 689)
No single metric tells the full story. See the XSWX:COPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
78GF Score
Get the complete analysis for XSWX:COPN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:COPN has been successfully added to your 
